Ramelteon

Generic Name
Ramelteon
Brand Names
Rozerem
Drug Type
Small Molecule
Chemical Formula
C16H21NO2
CAS Number
196597-26-9
Unique Ingredient Identifier
901AS54I69
Background

Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.

Indication

用于失眠症，特别适用于治疗难以入睡型失眠症。

Associated Conditions
Insomnia
Associated Therapies
-
Clinical Trials
Related News

Study of Efficacy of Ramelteon in Adults With Chronic Insomnia

Phase 3
Completed
Conditions
Chronic Insomnia
Interventions
Drug: Placebo
Drug: Ramelteon
First Posted Date
2008-05-05
Last Posted Date
2012-11-12
Lead Sponsor
Takeda
Target Recruit Count
405
Registration Number
NCT00671125

Safety and Efficacy of Ramelteon in Healthy Subjects

Phase 2
Completed
Conditions
Sleep Disorder
Interventions
Drug: Ramelteon
Drug: Placebo
First Posted Date
2008-05-05
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
75
Registration Number
NCT00671190

Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia

Phase 3
Completed
Conditions
Chronic Insomnia
Interventions
Drug: Placebo
Drug: Ramelteon
First Posted Date
2008-05-05
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
829
Registration Number
NCT00671255

Efficacy of Ramelteon in Subjects With Chronic Insomnia

Phase 3
Completed
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
Drug: Ramelteon
First Posted Date
2008-05-05
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
1213
Registration Number
NCT00671086

Long-Term Efficacy of Ramelteon on Endocrine Function in Adult Subjects With Chronic Insomnia

Phase 3
Completed
Conditions
Insomnia
Interventions
Drug: Ramelteon
Drug: Placebo
First Posted Date
2008-04-14
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
122
Registration Number
NCT00656994

Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon

First Posted Date
2008-03-25
Last Posted Date
2019-07-26
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
29
Registration Number
NCT00642694
Locations
🇺🇸

University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States

Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia

Phase 4
Completed
Conditions
ADHD With Sleep Onset Insomnia
Interventions
Drug: Placebo
Drug: Ramelteon
First Posted Date
2008-02-25
Last Posted Date
2013-05-24
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
32
Registration Number
NCT00622427
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

Ramelteon for a Nap Prior to a Night Shift

Not Applicable
Completed
Conditions
Healthy
Interventions
Drug: Ramelteon
Drug: placebo
First Posted Date
2008-01-16
Last Posted Date
2012-10-30
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
11
Registration Number
NCT00595075

Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia

First Posted Date
2008-01-16
Last Posted Date
2012-09-13
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
25
Registration Number
NCT00595504
Locations
🇺🇸

Freedom Trail Clinic, Boston, Massachusetts, United States

Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome

First Posted Date
2008-01-15
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
132
Registration Number
NCT00593736
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy